BioVaxys and Sona Nanotech Enter Research Collaboration
VANCOUVER, British Columbia, and HALIFAX, Nova Scotia, May 7th, 2025– BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys”) and Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (“Sona”) announce today that they have entered into a Research Agreement (“Agreement”) to collaborate on the development of new cancer therapeutics based on BioVaxys’ DPX™ Immune Educating Platform (“DPX”) in combination with Sona’s Targeted Hyperthermia Therapy™ (“THT”), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The heat for THT is delivered to tumors using infrared light that is absorbed by Sona’s proprietary biocompatible Gold Nanorod (“GNR”) technology which elicits a strong immune response.
